Granulomatous amoebic encephalitis (GAE)[2] is a rare, often fatal, subacute-to-chronic
central nervous system disease caused by certain species of free-living
amoebae[3] of the genera Acanthamoeba, Balamuthia and Sappinia.[4][5] The term is most commonly used with Acanthamoeba. In more modern references, the term "balamuthia amoebic encephalitis" (BAE) is commonly used when Balamuthia mandrillaris is the cause.[6][7][8][9]
Symptoms and signs
GAE starts slowly, with symptoms like headache, nausea, dizziness, irritability and a low-grade fever. The CNS symptoms depend on the part of the brain that is infected. Changes in behavior are an important sign. Other CNS signs may include
seizures,
focal neurologic signs,
diplopia (double vision),
cranial nerve palsies,
ataxia, confusion, and personality changes.[1]
Some of the symptoms may mimic
glioma (especially
brainstem glioma), or other brain diseases, which may hamper timely diagnosis. The symptoms are caused by inflammatory
necrosis of brain tissue brought on by compounds released from the organisms.[citation needed]
Diagnosis
The condition can be difficult for doctors to diagnose, because it is a rare disease.[10] A
brain biopsy will reveal the presence of infection by pathogenic amoebas. In GAE, these present as general inflammation and sparse
granules. On microscopic examination, infiltrates of amoebic
cysts and/or
trophozoites will be visible.[11]
Like with Acanthamoeba, infection of the brain with this organism rapidly turns fatal in most cases.[13] However some survivors have been reported:
Two patients survived after being successfully treated with a therapy consisting of
flucytosine,
pentamidine,
fluconazole,
sulfadiazine, and
azithromycin.
Thioridazine or
trifluoperazine was also given. Successful treatment in these cases was credited to "awareness of Balamuthia as the causative agent of encephalitis and early initiation of antimicrobial therapy."[14]
In 2018 a metagenomic sequencing analysis identified
Nitroxoline as
amoebicidal agent against the Balamuthia mandrillaris.[16]
In 2021 a patient recovered after treatment with
nitroxoline.[17][18] The man had been given a recommended drug therapy (pentamidine, sulfadiazine, azithromycin/
clarithromycin, fluconazole, flucytosine, and
miltefosine) but progressed negatively. Therefore with the permission of the
FDA the regime was complemented with the unapproved drug.
Nitroxoline had previously been identified via a
clinical metagenomic next-generation sequencing analysis to be a compound that could be
repurposed as an
amoebicidal agent against Balamuthia mandrillaris.[16] The brain abscess shrank only one week later and the man later recovered.
Prognosis
Even with treatment, CNS infection with Acanthamoeba is often fatal, and there are very few recorded survivors, almost all of whom had permanent
neurocognitive deficits.[12] The prognosis is largely influenced by the time of diagnosis, how virulent and sensitive the Acanthamoeba strain is, and, most crucially, the immune status of the affected person. Due to it commonly being an
opportunistic infection, the prognosis is generally poor, with a mortality rate approaching 90%.[1]
Sappinia pedata can cause GAE, however only one case of GAE due to S. pedata infection has ever been reported, and the patient survived without any long-term consequences.[19]
See also
Naegleriasis, an almost invariably fatal infection of the brain by the percolozoan Naegleria fowleri
^Sarica FB, Tufan K, Cekinmez M, Erdoğan B, Altinörs MN (July 2009). "A rare but fatal case of granulomatous amebic encephalitis with brain abscess: the first case reported from Turkey". Turkish Neurosurgery. 19 (3): 256–259.
PMID19621290.
^Akpek G, Uslu A, Huebner T, Taner A, Rapoport AP, Gojo I, et al. (August 2011). "Granulomatous amebic encephalitis: an under-recognized cause of infectious mortality after hematopoietic stem cell transplantation". Transplant Infectious Disease. 13 (4): 366–373.
doi:
10.1111/j.1399-3062.2011.00612.x.
PMID21338461.
S2CID31162954.